PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer

被引：0

作者：

Antonia, S. J. ^{[1
]}

Villegas, A. ^{[2
]}

Daniel, D. ^{[3
,4
]}

Baz, D. Vincente ^{[5
]}

Murakami, S. ^{[6
]}

Hui, R. ^{[7
,8
]}

Yokoi, T. ^{[9
]}

Chiappori, A. ^{[1
]}

Lee, K. H. ^{[10
]}

de Wit, M. ^{[11
]}

Cho, B. C. ^{[12
]}

Bourhaba, M. ^{[13
]}

Quantin, X. ^{[14
,15
]}

Tokito, T. ^{[16
]}

Mekhail, T. ^{[17
]}

Planchard, D. ^{[18
]}

Jiang, H. ^{[19
]}

Huang, Y. ^{[19
]}

Dennis, P. A. ^{[19
]}

Ozguroglu, M. ^{[20
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Canc Specialists North Florida, Jacksonville, FL USA

[3] Tennessee Oncol, Chattanooga, TN USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Hosp Univ Virgen Macarena, Seville, Spain

[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[7] Westmead Hosp, Sydney, NSW, Australia

[8] Univ Sydney, Sydney, NSW, Australia

[9] Kansai Med Univ Hosp, Hirakata, Osaka, Japan

[10] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea

[11] Vivantes Klinikum Neukoelln, Berlin, Germany

[12] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[13] Ctr Hosp Univ Liege, Liege, Belgium

[14] CHU Montpellier, Montpellier, France

[15] ICM Val dAurelle, Montpellier, France

[16] Kurume Univ Hosp, Kurume, Fukuoka, Japan

[17] Florida Hosp, Inst Canc, Orlando, FL USA

[18] Gustave Roussy, Villejuif, France

[19] AstraZeneca, Gaithersburg, MD USA

[20] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2017年 / 99卷 / 05期

关键词：

D O I：

10.1016/j.ijrobp.2017.09.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA-4

引用

页码：1314 / 1315

页数：4

共 50 条

[1] PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
Schulz, C.
Laack, E.
Wolff, T.
Rueckert, A.
Reck, M.
Faehling, M.
Fischer, J. R.
de Wit, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 270
[2] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
de Wit, M.
Laack, E.
Schulz, C.
Wolff, T.
Rueckert, A.
Reck, M.
Faehling, M.
Fischer, J.
STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S24 - S24
[3] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
Laack, H. -E.
Schulz, C.
Wolff, T.
Rueckert, A.
Reck, M.
Faehling, M.
Fischer, J. R.
de Wit, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 186 - 187
[4] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
Paz-Ares, L.
Villegas, A.
Daniel, D.
Baz, D. V.
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
ANNALS OF ONCOLOGY, 2017, 28
[5] Phase 3, Double-Blind, Placebo-Controlled Study of MEDI4736 After Chemoradiation in Stage III, Locally Advanced, Unresectable NSCLC (PACIFIC)
Cho, Byoung Chul
Kim, Joo-Hang
Villegas, Augusto
Frusch, Nicolas
Murakami, Shuji
Shi, Kelvin
Ibrahim, Ramy
Ballas, Marc
Antonia, Scott J.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S668 - S668
[6] Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer
Guo, Matthew Z.
Murray, Joseph C.
Ghanem, Paola
Voong, K. Ranh
Hales, Russell K.
Ettinger, David
Lam, Vincent K.
Hann, Christine L.
Forde, Patrick M.
Brahmer, Julie R.
Levy, Benjamin P.
Feliciano, Josephine L.
Marrone, Kristen A.
CLINICAL LUNG CANCER, 2022, 23 (07) : 620 - 629
[7] A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN
Wang, Luhua
Chen, Ming
Kato, Ken
Wyrwicz, Lucjan
Smyth, Elizabeth Catherine
Jiang, Anastasia
Zhang, Di
Robbins, Scott H.
He, Philip
Negro, Alejandra
Saba, Nabil F.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[8] Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
Hassanzadeh, Comron
Sita, Timothy
Savoor, Rohan
Samson, Pamela P.
Bradley, Jeffrey
Gentile, Michelle
Roach, Michael
Mohindra, Nisha
Waqar, Saiama
Kruser, Timothy J.
Robinson, Clifford
JOURNAL OF THORACIC DISEASE, 2020, 12 (11) : 6690 - 6700
[9] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
Volovat, Constantin
Bondarenko, Igor M.
Gladkov, Oleg A.
Elsaesser, Reiner
Buchner, Anton
Bias, Peter
Mueller, Udo
SPRINGERPLUS, 2015, 4
[10] Boosting immune response with copanlisib in locally advanced unresectable non-small cell lung cancer starting durvalumab consolidation: A phase Ib study
Hao, Z.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S114 - S115

← 1 2 3 4 5 →